Skip to content

the role of galectin-3 in the evaluation of cardiac resynchronization therapy

Galectin-3 for prognosis of HF after CRT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044127
Enrollment
Unknown
Registered
2021-03-11
Start date
2016-01-01
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Case series:CRT treatment

Sponsors

Zhenjiang First People's Hospital, Jiangsu Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
36 Years to 81 Years

Inclusion criteria

Inclusion criteria: Consecutive patients referred to our department for primary implantation of CRT were prospectively included from January 2016 to December 2017. Patients were selected for CRT in the presence of severe LV dysfunction (LVEF = 150ms or 120-149ms with left bundle branch block (LBBB), New York Heart Association (NYHA) class II-IV and refractory to optimal medical therapy.

Exclusion criteria

Exclusion criteria: Patients with histories of recent myocardial infarction (< 3 months), atrial fibrillation, pulmonary hypertension, hepatic and renal failure, malignant cancer, pulmonary fibrosis, anemia and thyroid disease were excluded from the study.

Design outcomes

Primary

MeasureTime frame
HF hospitalization and cardiac mortality;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactYongwei Yao

Zhenjiang First People's Hospital, Jiangsu Province

zjywyao78@163.com+86 13913439030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026